
Shire is set to sweeten its $30 billion bid for Baxalta by offering 40% of the total, or $12 billion, …

Shire has seen an application for its dry eye treatment lifitegrast rejected by the US regulator. The FDA says it …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions

